Timolol
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Timolol
Timolol: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Timolol, so there is currently no new predicted indication. The uses recorded for this drug are listed below. They are the drug’s own recorded uses, not model candidates.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 5 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| glaucoma | licence in another country |
| ocular hypertension | licence in another country |
| open-angle glaucoma | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| hypertension |
| hypertensive disorder |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 1279H | Timoptol | Eye drops 5 mg (as maleate) per mL, 5 mL | Valid |
Safety Considerations
Product Information warnings and contraindications are not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for safety information.
The following items come from the data compiled for this report:
- Disease associations flagged as contraindications (knowledge graph, not label text): orthostatic hypotension, anxiety and mood disorders, kidney and liver disease, pancreatitis, systemic lupus erythematosus, diabetes mellitus and diabetic ketoacidosis, gout, myasthenia gravis and other neuromuscular junction disease, and several electrolyte and metabolic disorders. These should be verified against the PI.
- Class considerations: Non-selective beta-blockade carries a risk of bronchospasm and cardiac effects, particularly in patients with chronic lung disease. A 1981 report found marked cardiovascular and pulmonary effects of topical timolol in glaucoma patients with COPD, bradycardia or cardiac insufficiency. A case of timolol-induced interstitial lung disease has also been reported.
- Drug interactions: 100 interactions are recorded. The only one rated Major in the displayed list is epinephrine. Most others are Moderate (for example corticosteroids such as hydrocortisone, dexamethasone, betamethasone, budesonide and triamcinolone; anticholinergics such as atropine, hyoscyamine and dicyclomine; and bupropion, morphine, cimetidine, canagliflozin, dapagliflozin and chlorpropamide). Aspirin and magnesium oxide are rated Minor.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.